Related Experiment Video
Updated: Jun 2, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Inflammation and thrombosis in diabetes
Katharina Hess1, Peter J Grant
1Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, LIGHT Laboratories, Clarendon Way, University of Leeds, Leeds, UK.
Insights
Patients with diabetes have a heightened risk of cardiovascular events due to a prothrombotic state. This increases cardiovascular mortality and reduces antithrombotic therapy effectiveness.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Endocrinology
Background:
- Patients with diabetes mellitus face elevated risks of cardiovascular morbidity and mortality.
- Atherothrombosis, characterized by atherosclerotic lesion disruption and thrombus formation, is a leading cause of death in diabetic individuals.
- Diabetic patients exhibit a prothrombotic state involving hyper-reactive platelets, increased pro-thrombotic markers, and impaired fibrinolysis.
Purpose of the Study:
- To elucidate the mechanisms underlying the prothrombotic state in diabetes.
- To understand the impact of insulin resistance, dysglycemia, and inflammation on thrombotic risk.
- To highlight the implications for cardiovascular risk and antithrombotic therapy efficacy.
Main Methods:
- Review of existing literature on diabetes, atherothrombosis, and hemostasis.
- Analysis of the interplay between metabolic and inflammatory factors in platelet and coagulation pathways.
- Examination of the effects on clot structure and fibrinolysis.
Main Results:
- Diabetes is associated with hyper-reactive platelets and increased pro-thrombotic markers.
- Insulin resistance, dysglycemia, and inflammation significantly contribute to this prothrombotic state.
- The prothrombotic state affects platelet function, coagulation factors, and clot structure, leading to impaired fibrinolysis.
Conclusions:
- The prothrombotic state in diabetes significantly elevates cardiovascular risk.
- This state may explain the diminished response to standard antithrombotic therapies.
- Optimized antithrombotic strategies are crucial for reducing cardiovascular mortality in diabetic patients.
Abstract:
Patients with diabetes mellitus are at increased risk of cardiovascular morbidity and mortality. Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the most common cause of death among these patients. Following plaque rupture, adherence of platelets is followed by local activation of coagulation, the formation of a cross-linked fibrin clot and the development of an occlusive platelet rich fibrin mesh. Patients with diabetes exhibit a thrombotic risk clustering which is composed of hyper-reactive platelets, up regulation of pro-thrombotic markers and suppression of fibrinolysis. These changes are mainly mediated by the presence of insulin resistance and dysglycaemia and an increased inflammatory state which directly affects platelet function, coagulation factors and clot structure. This prothrombotic state is related to increased cardiovascular risk and may account for the reduced response to antithrombotic therapeutic approaches, underpinning the need for adequate antithrombotic therapy in patients with diabetes to reduce their cardiovascular mortality.
Related Concept Videos
Diabetic Retinopathy
Venous Thrombosis I: Introduction
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type I Diabetes II: Pathophysiology
Complications of Diabetes Mellitus
Anticoagulant Drugs: Low-Molecular-Weight Heparins
